- Integer Holdings Corporation ITGR posted Q3 sales of $305.57 million, +30% Y/Y, beating the consensus of $303.23 million. Q3 adjusted EPS more than doubled to $1.05, ahead of the consensus of $0.84.
- Adjusted operating income expanded 86% to $47 million, while adjusted EBITDA improved 63% to $60 million.
- Integer also agreed to acquire Oscor Inc, a privately held medical device company, for $220 million. Oscor broadens Integer's product portfolio, expands its R&D capabilities, and adds low-cost manufacturing capacity.
- The transaction is expected to be accretive EPS in 2022, increasing Integer's EPS growth rate by low-single-digit.
- Integer announced the construction of a manufacturing facility in Ireland. The Company expects to spend approximately $30 million over five years on the facility.
- Guidance: Integer expects FY21 sales of $1.205 billion - $1.22 billion, compared to earlier guidance of $1.20 billion - $1.22 billion.
- The Company raised adjusted EPS guidance to $3.90 - $4.15 (consensus $3.88) from $3.66 - $4.03 expected earlier.
- Price Action: ITGR shares are up 2.30% at $93.60 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in